Helsinki-based startup CurifyLabs Oy has recently announced that it has been awarded a grant from the European Innovation Council (EIC) Accelerator Programme. CurifyLabs is committed to automating and streamlining the drug compounding process, making personalized treatments better, safer and easier to produce. This grant will be used to further advance the company’s MiniLab solution for personalised medicines manufacture, specifically at hospital and community pharmacies.
CurifyLabs was selected from a highly competitive pool of 476 applications, with only 32 deeptech companies chosen to receive funding. With the 100%, non-dilutive grant from the EIC, CurifyLabs will be able to standardise the process for developing 3D printing compatible drug formulations and quality control solutions. This will ultimately allow the MiniLab solution to be highly scalable across different therapeutic areas, with a particular focus on paediatrics and oncology.
The MiniLab is a unique and proprietary manufacturing solution, which enables tailored 3D printing of bespoke pharmaceuticals by compounding pharmacies. It has been designed to support compounding pharmacies in eliminating the laborious and time-consuming manual manufacturing of pharmaceuticals and delivering tailored medicines with robust quality control at the point-of-care.
Age, gender, lifestyle, genetic and metabolic differences all affect the way patients respond to therapies. Standardised dosing and therapies can lead to poor treatment efficacy, undesirable side effects and adherence issues, particularly in paediatrics and oncology. Practical manufacturing methods are needed for these personalised medicines and the MiniLab technology automates what has been a largely manual process, allowing for a significant reduction in complexity and time.
Charlotta Topelius, Founder and Chief Executive Officer, CurifyLabs, commented: “We are delighted to have received this prestigious grant from the European Innovation Council to further develop MiniLab and bring a high-quality 3D printing solution for compounding of personalised medicines to pharmacists across Europe. There’s a large and growing demand for personalised therapies and our solution is aimed at helping compounding pharmacists meet those needs.”
The MiniLab is already successfully piloted by several innovative pharmacies in multiple European markets including Finland, Spain, Switzerland, Germany and the Netherlands.
